Skip to main content

Table 1 Results of HIV molecular testing, Antigen/Antibody screening assay, and CD4 count from time first presentation (June 2014) to initiation of ARV therapy

From: Correction to: Rapid development of HIV elite control in a patient with acute infection

Time Viral Load
(RNA copies/ml)
Forth Generation Antigen/Antibody HIV Test
(s/co –relative quantity of HIV Ab)
Confirmatory Test CD4+ T Cells/uL (%)
Viral Load SCA ARCHITECT (S/Co) VIDAS (S/Co) GS INNO-LIA
Jun 2014 71550a 1 b NEG NEG
Oct 2014 <  200 11.1c 13.72 c gp41 (3+), p31 (1+), p24 (3+), p17 (1+) c
Nov 2014 <  40 616 (45%)
Dec 2014
Oct 2015 <  40 459 (46%)
Apr 2016 <  40 558 (40%)
Sep 2016 0.84d
Antiretroviral therapy commenced September 2016 d
 Oct 16 585 (47%)
  1. Fourth Generation HIV Antigen/Antibody test: ARCHITECT® Abbott; VIDAS® BioMerieux; GS = GeneScreen® Bio-Rad, INNO-LIA, Fujirebio®
  2. SCA Single copy assay, S/Co Signal/cutoff
  3. a Retrospective molecular test on stored sample from June 2014
  4. b Read as equivocal value at time of testing
  5. c Positive test
  6. d ARV commenced on clinical grounds-patient presented with furunculosis